SecBot SecBot

RLYB

Rallybio Corp
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001739410 Biotech & Drug Discovery
$16.50 −0.14 (−0.84%)
Oct 26 4:00 PM ET · prev $16.64
Market cap
$87.1M
Micro cap
1 year
+230.0%
from $5.00 · Oct 27
30 days
−3.2%
from $17.05
52-week range
$4.33–17.22
−4% from high · low Feb 17
Avg volume 20D
13.0K
Oct 20 spike 102.6K
Short interest
49.2K
≈0.9% of shares · −11.4%
Days to cover
4.9
at average volume
Insider net
+$4.2M
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest NEUTRAL Rallybio filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Avenzo…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $4.2M at an average $13.98. 1 insider sold $4.0K. Price is 18% above their cost.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 2 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$1.440 → −$1.440 over 90 days.

  • Short sellersSTEADY

    Short interest −11.4% to 49.2K shares. 4.9 days to cover, ≈0.9% of shares.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD199,907$3.2M
VANGUARD CAPITAL MANAGEMENT LLCADD172,497$2.8M
CITADEL ADVISORS LLCDOUBLED72,200$1.2M
BlackRock, Inc.ADD30,332$485.3K
UBS Group AGNEAR_EXIT146$2.3K
JPMORGAN CHASE & CONEAR_EXIT9$145.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2025
Recent actions
DateFirmActionRating
Apr 15, 2025Jones Trading
DOWNGRADE
DOWNGRADEHold
Apr 9, 2025HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Mar 17, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Feb 12, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 13, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Dec 3, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$4.2M
bought · 1 insider
$4.0K
sold · 1 insider
+18.0%
vs their $13.98 cost
DateInsiderTypeValue
Oct 16, 2026
Soteropoulos Paula
Director
EXERCISE$8.5K
Oct 16, 2026
Boudreau Helen M
Director
EXERCISE$31.5K
Oct 12, 2026
Hopfner Robert Lorne
Director
EXERCISE$69.9K
Oct 12, 2026
Hopfner Robert Lorne
Director
EXERCISE$8.5K
Oct 12, 2026
Hopfner Robert Lorne
Director
EXERCISE$31.5K
Oct 9, 2026
Lieber Jonathan I
Chief Financial Officer
EXERCISE$23.8K
Oct 6, 2026
Uden Stephen
Chief Executive Officer
EXERCISE$136.5K
Sep 29, 2026
Lieber Jonathan I
Chief Financial Officer
EXERCISE$30.4K

Earnings setup

Estimates
−$1.44
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.44-$1.44–-$1.44+0.0%$0.00
Next Q-$1.60-$1.60–-$1.60+0.0%$0.00
Current FY-$5.52-$5.52–-$5.52-2.2%$0.00
Next FY-$3.60-$3.60–-$3.60+0.0%$0.00

Short side

FINRA· Sep 30, 2026
49,245
shares short
-11.4%
vs prior settlement
4.9
days to cover
≈0.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
The SEC declared effective Rallybio Corp's S-4 registration statement (File No. 333-297483) on October 15, 2026. This…
EFFECT — Impact 4/10
Oct 16, 2026 Insider
Soteropoulos Paula acquired via exercise 3,562 shares
Director @ $2.38 ($8.5K)
Oct 16, 2026 Insider
Boudreau Helen M acquired via exercise 2,062 shares
Director @ $15.28 ($31.5K)
Oct 14, 2026 SEC
Rallybio filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Avenzo…
S-4/A — Impact 6/10
Oct 12, 2026 Insider
Hopfner Robert Lorne acquired via exercise 9,196 shares
Director @ $7.60 ($69.9K)
Jul 15, 2026 SEC
Rallybio Corp (RLYB) filed an S-4 registration statement for a proposed reverse merger with private biotech Avenzo…
S-4 — Impact 6/10
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
199,907 shares ($3.2M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
172,497 shares ($2.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 12, 2026
Earnings date
RLYB Q1 2026 Earnings Before Market Open — 2026-05-12
Mar 17, 2026
Earnings date
RLYB Q4 2025 Earnings After Market Close — 2026-03-17
Mar 6, 2026
Clinical Trial
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Phase 2 · TERMINATED

SecBot reports

6 filings · 2 bullish · 0 bearish · 1 mixed · 3 neutral
All RLYB filing & press-release reports (6)